Gerald Batist, Joo Yeoun Park, Jeremy Drees, Takashi Kangas and Daniel Saltzman* (USA)
Compassionate use of Saltikva was sought for a patient with stage 4, metastatic pancreatic cancer. Approval was granted for an n=1 multiple dose (every 2 week) trial with concomitant FOLFIRINOX. Now, at 15 months, this patient has not experienced any toxicity to Saltikva, continues therapy, has normalized CA19-9 levels, maintained her immunologic cell populations despite cytotoxic chemotherapy, demonstrated a strong NK cell response, and has a radiologic regression of metastatic tumor burden with a complete absence of tumor activity by PET scan.
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Hindi